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n the United States, an estimated 2.7 to 3.9 million people have chronic hepatitis C (CHC), making it the most common blood-borne infection. 1 Roughly 75% to 85% of acute hepatitis C infections persist as CHC. [2] [3] [4] [5] The majority of infected people are unaware of their condition because most acute hepatitis C infections are asymptomatic or show nonspecific mild symptoms, 6, 7 and symptomatic complications (eg, cirrhosis) usually take >2 decades to develop. 8 The current incidence of acute hepatitis C ranges from 15,000 to 20,000 new infections per year, and recurrent infection rates after successful treatment range from 1% to 22%. 9 Infections peaked at an estimated 300,000 new infections per year in the late 1980s. 10 The prevalence of hepatitis C viremia in the population peaked in 1994, but given the long course of disease, the prevalence of decompensated cirrhosis has continued to rise. The age-adjusted mortality rate for hepatitis C increased between 1999 and 2007 to 4.58 deaths per 100,000 people, surpassing that of HIV in 2006. 11 Recent data from the Centers for Disease Control and Prevention (CDC) indicate that the ageadjusted CHC mortality rate has continued to increase to 4.65 deaths per 100,000 in 2010. 12 Without treatment, morbidity and mortality caused by CHC are forecasted to peak in 2030 in the United States with 24,300 newly diagnosed decompensated cirrhosis cases, 14,300 hepatocellular carcinoma cases, 3100 liver transplants, and 34,900 deaths. 13 The cost of treating advanced liver disease in the United States was estimated at $6.5 billion in 2013, with an expected peak cost of $9.1 billion in 2024. 14 Recently available direct-acting antiviral drugs are highly effective in treating hepatitis C 15 and are usually well tolerated in interferon-free regimens that spare patients the adverse effects and lower efficacy of interferonbased treatment. The high cost of these drugs has led some private health insurance plans and Medicaid programs to restrict treatment to certain high-risk patients. 16 Universal treatment of all CHC patients should be the ultimate goal. However, in the setting of limited resources, proportionally more cases of decompensated cirrhosis can be prevented if treatment is prioritized to CHC patients at highest risk rather than treating all infected persons. Therefore, identifying patients with the highest risk of poor outcomes would allow more rational prioritization of treatment.
We hypothesized that prevalent diabetes mellitus is associated with increased risk of developing hepatic complications in CHC patients. To test this hypothesis, we studied the association of diabetes with the development of decompensated cirrhosis in a large population of CHC patients using a medical claims database of privately insured persons.
MATERIALS AND METHODS
This was a retrospective cohort study using the 2006 to 2013 Truven Health Analytics MarketScan Commercial Claims and Encounters database, including inpatient, outpatient, and outpatient pharmacy claims from employersponsored insurance plans covering employees and their dependents. Approximately 100 payers contributed to this dataset. An encrypted person identifier allows longitudinal follow-up. The Washington University Human Research Protection Office determined this study was exempt from Institutional Review Board oversight.
CHC was identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes. The ICD-9-CM diagnosis codes described by Kramer et al 17 were used to identify individuals with CHC, requiring at least one CHC code (ICD-9-CM, 070.44, 070.54, or V02.62) on an inpatient facility claim or Z2 codes spaced >30 and r180 days apart in outpatient/provider claims, as described by Klabunde et al. 18 For people identified solely by outpatient/provider claims, the first indicator of hepatitis C infection was expanded to include chronic, unspecified, or acute hepatitis C (ICD-9-CM, 070.41, 070.44, 070.51, 070.54, 070.70, 070.71, or V02.62), whereas the second code was required to be specific for CHC. Diagnostic laboratory claims from outpatient providers (see Appendix for definition, Supplemental Digital Content 1, http://links.lww.com/JCG/A247) were not used to identify CHC or other diagnoses as the conditions coded on these claims might be used for rule-out conditions rather than established diagnoses.
The study population included CHC patients 18 years and older having complete medical and prescription drug insurance coverage for a minimum of 6 months after meeting the definition of CHC (see above), to identify baseline conditions. Persons with decompensated cirrhosis (ie, bleeding esophageal varices, ascites, hepatic encephalopathy, hepatocellular carcinoma, spontaneous bacterial peritonitis, or hepatorenal syndrome) or liver transplant identified during the baseline period were excluded.
Primary Exposure and Other Baseline Characteristics
Exposures were identified during the 6-month baseline period. Prevalent diabetes mellitus was defined by Z1 inpatient facility claim(s) with an ICD-9-CM diagnosis code for diabetes (249.00 to 250.93 or 648.00 to 648.04) or Z2 outpatient/provider claims coded for diabetes >30 days apart, or Z1 paid prescription(s) for an oral hypoglycemic medication or insulin. Cirrhosis at baseline was identified using Z1 ICD-9-CM diagnosis codes for cirrhosis, portal hypertension, or nonbleeding esophageal varices to improve accuracy for identifying cirrhosis. 19 HBV and HIV infections were identified using Z1 inpatient facility claim(s) or Z2 outpatient/provider claims coded for the condition >30 days apart. Alcoholic liver disease/alcohol abuse and obesity were identified by Z1 ICD-9-CM diagnosis code as these conditions do not require diagnostic evaluation (see Appendix, Supplemental Digital Content 1, http://links.lww.com/JCG/A247). CHC treatment during the baseline period was defined as Z1 paid pharmacy prescription(s) for interferon-a, ribavirin, boceprevir, or telaprevir. The number of health care encounters (hospitalizations and outpatient visits) was calculated in the 6 months preceding the date when the CHC definition was met in a subset of patients who had insurance coverage in that period.
Outcomes
Follow-up started 6 months after the date when the CHC definition was met. Diabetic and nondiabetic CHC patients were followed to identify new diagnosis of decompensated cirrhosis (the primary outcome), including any of bleeding esophageal varices, ascites, hepatic encephalopathy, hepatocellular carcinoma, spontaneous bacterial peritonitis, or hepatorenal syndrome. Secondary outcomes included hepatocellular carcinoma and a composite outcome of death or liver transplant. Outcomes were identified using ICD-9-CM diagnosis and procedure codes (see Appendix, Supplemental Digital Content 1, http:// links.lww.com/JCG/A247) present on Z1 claim. Followup continued until an outcome, end of insurance coverage, or December 31, 2013; whichever came first. Figure 1 illustrates the study design.
Statistical Analyses
The wfor gender, age group, alcoholic liver disease/alcohol abuse, obesity, HBV coinfection, HIV coinfection, recent interferon-based CHC treatment, and diabetes. Hazard ratios (HR) and 95% Wald confidence intervals (CI) were reported. Separate multivariable Cox proportional hazards model tested the interaction of diabetes with baseline cirrhosis, the interaction of CHC treatment with baseline cirrhosis, and the interaction of diabetes with CHC treatment. A subanalysis including only persons with Z3 years of follow-up was also performed [n = 16,750 persons; median follow-up = 4.4 y; interquartile range (IQR), 3.6 to 5.6 y]. SAS Enterprise Guide version 7.1 (SAS Institute Inc., Cary, NC) was used for all data management and analyses.
RESULTS
We identified 75,805 CHC patients with at least 6 months insurance coverage beginning on the date when the CHC definition was met, who were enrolled in employersponsored health insurance plans in the United States from January 1, 2006 to June 30, 2013. Figure 2 shows the algorithm with inclusion/exclusion criteria that resulted in the final study population. The median years of follow-up was 1.9 years (range, 0.5 to 8 y). The study population was predominantly male (61.8%) and had a median age of 53 years (range, 18 to 64 y). Insured dependents of employees constituted 32.3% of the study population. Diabetes mellitus was identified in 10,317 (13.6%) of the CHC population at baseline. Among 10,317 diabetics, there were 2840 persons identified only by diabetes medications. Of the 7477 individuals having ICD-9-CM diagnosis codes for diabetes, there were 1289 (17.2%) persons with at least 1 ICD-9-CM diagnosis code for type 1 diabetes and 79 (1.1%) persons with at least 1 code for secondary diabetes. Diabetic CHC patients were more likely to be male, older, obese, and have cirrhosis at baseline and were less likely to be coinfected with HIV and have received CHC treatment during the baseline period compared with nondiabetic CHC patients ( Table 1 ). The median follow-up time for diabetic CHC patients (1.77 y; IQR, 0.96 to 3.09) was shorter than that of nondiabetic CHC patients (1.88 y; IQR, 0.99 to 3.41; P < 0.0001). Diabetic patients had more health care encounters in the 6 months before the date when the CHC definition was met (median 7 encounters; IQR, 4 to 12) compared with nondiabetics (median 5; IQR, 3 to 10; P < 0.0001), in a subset of 44,657 patients with complete insurance coverage in the 6-month period before meeting the CHC definition. Diabetic CHC patients had higher incidence of all conditions comprising the diagnosis of decompensated cirrhosis (bleeding esophageal varices, ascites, hepatic encephalopathy, hepatocellular carcinoma, spontaneous bacterial peritonitis, and hepatorenal syndrome) as well as death, stratified by having cirrhosis at baseline ( Table 2) . People with both cirrhosis and diabetes at baseline had higher probability of progressing to decompensated cirrhosis than people with only cirrhosis, only diabetes, or neither condition (Fig. 3) . In multivariable Cox proportional hazards models diabetes was associated with significantly increased risk of decompensated cirrhosis in persons coded for cirrhosis at baseline (adjusted HR = 1.42; 95% CI, 1.29-1.56), and in persons not coded for cirrhosis at baseline (adjusted HR = 1.86; 95% CI, 1.69-2.06; Table 3 ). Male gender and alcoholic liver disease/ alcohol abuse were independently associated with higher risk of decompensated cirrhosis. Baseline CHC treatment was associated with significantly decreased risk of decompensated cirrhosis in both models, with the protective effect greater in patients with baseline cirrhosis (interaction P < 0.001, Table 3 ). The interaction between diabetes and baseline cirrhosis was significantly associated with decompensated cirrhosis (P < 0.001) in a separate multivariable Cox proportional hazards model.
Secondary Outcomes and Subanalysis
In a separate multivariable Cox proportional hazards model, diabetes was associated with increased risk of hepatocellular carcinoma in persons with baseline cirrhosis (adjusted HR = 1.27; 95% CI, 1.04-1.53) and in persons without baseline cirrhosis (adjusted HR = 1.82; 95% CI, 1.52-2.18). The risk of hepatocellular carcinoma associated with diabetes was significantly higher in persons with baseline cirrhosis compared with persons without baseline cirrhosis (interaction P = 0.008). Diabetes was also associated with increased risk of the composite outcome of death/liver transplant (adjusted HR = 1.26; 95% CI, 1.04-1.52) in persons with baseline cirrhosis and significantly higher risk in persons without baseline cirrhosis (adjusted HR = 2.01; 95% CI, 1.70-2.38; P < 0.001 for interaction term). In a subset analysis of the population with at least 3 years follow-up, diabetes was associated with increased risk of decompensated cirrhosis in both persons with baseline cirrhosis (adjusted HR = 2.08; 95% CI, 1.51-2.85) and without baseline cirrhosis (adjusted HR = 2.15; 95% CI, 1.74-2.66). The complete results of the secondary outcomes and subanalysis are included in the Appendix (Supplemental Digital Content 1, http://links.lww.com/JCG/ A247).
DISCUSSION
In this large population of CHC patients having employer-sponsored insurance in the United States, diabetes mellitus was independently associated with increased FIGURE 2. Algorithm with inclusion/exclusion criteria to identify patients with chronic hepatitis C from health insurer claims data. *The baseline period was defined as the first 6 months beginning on the date when the chronic hepatitis C definition was met.
risk of decompensated cirrhosis, hepatocellular carcinoma, and liver transplant/death in patients both with and without baseline cirrhosis. This information may help guide decision-making regarding early treatment with the newly available direct-acting antivirals and appropriate management of diabetes.
Prior research suggests an association of diabetes, 20,21 insulin resistance, 20, [22] [23] [24] [25] [26] and serum glucose 27 with progression of hepatic fibrosis in CHC patients. Fewer studies looked at the association of diabetes with hepatocellular carcinoma [28] [29] [30] and other hepatic complications. 30, 31 These associations between diabetes and hepatic complications have not been firmly established as the studies were crosssectional, 20, [22] [23] [24] [25] [26] [27] 32 had small sample sizes, 21, 23 and/or included highly selected CHC populations. 21, 28, 29, 31 Results from 1 study 33 were difficult to interpret because a temporal relation between CHC and diabetes was not established.
Our results showed that older age was associated with higher risk to develop decompensated cirrhosis. This is not unexpected, as older age is likely a marker for longer duration of infection, and decompensated cirrhosis usually takes >2 decades to develop in CHC patients. 8 HIV and HBV coinfections were not significantly associated with decompensated cirrhosis. In agreement with prior research, 21, 26, 34 we found that male gender was associated with increased risk of decompensated cirrhosis. Despite the fact that interferon-based CHC treatment was only identified in the baseline 6 months beginning on the date when the definition of CHC was met, treatment was independently associated with lower risk of decompensated cirrhosis. Baseline treatment had a larger protective effect in people with baseline cirrhosis than without baseline cirrhosis. The outcome of antiviral therapy cannot be assessed in our administrative data.
The role of hepatitis C virus infection in the development of diabetes is controversial. [35] [36] [37] [38] [39] Liver cirrhosis can lead to diabetes (ie, hepatogenous diabetes 40 ). There were only 79 persons with ICD-9-CM diagnosis codes for secondary diabetes in our study population who possibly had hepatogenous diabetes or other types of secondary diabetes. Given the limitations of administrative databases, we cannot address the biological role of diabetes in liver disease progression. However, we were able to demonstrate that prevalent diabetes mellitus in CHC patients, regardless of whether it resulted from the hepatitis C infection, cirrhosis, or was due to other factors, was significantly associated with higher risk of liver disease progression. Because of the observational nature of this study, a causal association cannot be inferred between diabetes and decompensated cirrhosis. However, a diagnosis of diabetes can be used to assess the risk of progression to decompensated cirrhosis in CHC patients. Prior research has shown an association between glycemic control and metformin therapy with improved survival and lower risk of hepatic complications. 41 Patients with chronic liver disease and diabetes need appropriate diabetes management, and may also benefit from earlier antiviral treatment if they have CHC.
Limitations and Strengths
There were several limitations to this study. Using administrative data, we can only identify conditions that are diagnosed and coded on claims. Cirrhosis might be asymptomatic (therefore not coded on medical claims), which possibly resulted in misclassification. To minimize this bias, we used the first 6 months beginning on the date when the CHC definition was met to identify baseline conditions, including cirrhosis. With this baseline time period patients who underwent liver assessment soon after coding of CHC will be classified correctly, if the cirrhosis was diagnosed and coded. The time when individuals were infected with hepatitis C virus cannot be determined from claims data (ie, left censoring). Because CHC is usually asymptomatic and diabetics had higher number of health care encounters than nondiabetics, diabetics may be more likely to be screened and diagnosed with CHC earlier than nondiabetics, resulting in entry into our study population earlier in the course of their CHC. This would most likely result in a bias toward the null hypothesis, which would suggest that the association of diabetes and CHC with decompensated cirrhosis may be even stronger than we observed. Prior research suggests impaired glucose tolerance is associated with liver complications and lower survival in persons with cirrhosis, 42, 43 including cirrhosis related to hepatitis C. 44 However, due to the administrative nature of our data, we cannot accurately identify persons with impaired glucose tolerance to study this factor. If persons with impaired glucose tolerance have higher risk of developing liver complications and we classified them as nondiabetic, this will lead to bias toward the null hypothesis and an underestimate of the impact of diabetes on our study outcomes.
The study population consisted of beneficiaries of employer-sponsored insurance plans, which is not completely representative of the US population. ICD-9-CM diagnosis codes are not perfectly accurate, although the codes for CHC and cirrhosis were validated in VA FIGURE 3. Kaplan-Meier curves of decompensated cirrhosis-free survival stratified by cirrhosis and diabetes at baseline. Decompensated cirrhosis included any of: bleeding esophageal varices, ascites, hepatic encephalopathy, hepatocellular carcinoma, spontaneous bacterial peritonitis, or hepatorenal syndrome. Neither = neither cirrhosis nor diabetes, both = both cirrhosis and diabetes. Interaction testing for association of diabetes and baseline cirrhosis with decompensated cirrhosis (P < 0.001).
Interaction testing for association of chronic hepatitis C treatment and baseline cirrhosis with decompensated cirrhosis (P < 0.001).
Interaction testing for association of chronic hepatitis C treatment and diabetes with decompensated cirrhosis in model of persons with baseline cirrhosis (P = 0.919) and in model of persons without baseline cirrhosis (P = 0.792).
*The baseline period was defined as the first 6 months beginning on the date when the chronic hepatitis C definition was met. HR indicates hazard ratio.
administrative data with positive and negative predictive values of 93% and 92%, respectively, for CHC and 90% and 87%, respectively, for cirrhosis. 17 ICD-9-CM codes for diabetes mellitus have been validated in administrative data using both inpatient and outpatients records in elderly patients with cancer 45 (75.1% sensitivity and 95.1% specificity) and in elderly people treated by primary care physicians 46 (62.2% sensitivity and 97.2% specificity). In addition to inpatient and outpatient records, we used paid prescriptions for antidiabetic medications to identify diabetes; this likely improved the sensitivity to identify diabetes in our study.
The median follow-up in our study was 1.9 years, which might not be long enough to identify liver complications. To address this limitation, we performed a subanalysis including only persons with at least 3 years of follow-up, which demonstrated approximately 2-fold increased risk of decompensated cirrhosis associated with diabetes in persons with and without baseline cirrhosis. This is consistent with the Kaplan-Meier curves in Figure 3 in which the survival curve for diabetics diverges from the curve for nondiabetics with longer follow-up time.
The strengths of this study include the large study population including people from all regions in the United States. Our results are generalizable to adults with private insurance. We excluded persons with baseline decompensated cirrhosis to establish temporality of the association between diabetes and decompensated cirrhosis. In addition, our analyses showed that diabetes was consistently associated with not only decompensated cirrhosis, but also hepatocellular carcinoma and liver transplant/ death in people with baseline cirrhosis and in people without baseline cirrhosis.
CONCLUSIONS
CHC patients with diabetes mellitus had increased risk of decompensated cirrhosis and other hepatic complications in a population of persons with employer-sponsored health insurance in the United States. In the presence of limited fiscal resources and the inability to pay for treatment of all hepatitis C patients, persons with CHC and diabetes might benefit from prioritization and earlier treatment with one of the newer direct-acting antiviral regimens.
